Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
about
Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.17β-estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cellsPotential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABLNotch signaling in skeletal health and disease.Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.Molecular profiling of childhood cancer: Biomarkers and novel therapiesA review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockadeTherapeutic modulation of Notch signalling--are we there yet?Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.The emerging roles of Notch signaling in leukemia and stem cells.
P2860
Q26766395-C41592C3-197B-455E-B1F4-4291DEF2BE54Q30235105-EC1E6C67-5711-4417-A2F6-8F52AAFFA914Q34475754-88E8BC73-A606-4EA5-A855-900A4E6701BBQ34963991-53A45322-EFE5-45F5-91BA-28F0E075C807Q35596540-64EF73F3-072C-4514-B911-8099DC73ECF8Q35848797-260E7D03-F4CE-4818-84D4-BC69BB74385AQ36024533-744FA10B-DE72-49BF-9088-6BDA512A919BQ36250783-7EC11B0A-8F12-4F96-ADFB-F699F170F33CQ36888962-36766C6D-1974-4966-9F89-A73774D28AFDQ36941324-62FC7FDA-73FE-4797-95FD-E784BC9C669BQ38208211-C32D4254-C57C-4FA4-9F40-E77B93C889C0Q41195048-97925571-C82D-4436-964B-4450EF9A0634Q41708887-DA39446C-2D7F-493E-87A8-BA1EA2E8192AQ42560184-EFC69C0F-F6D7-42E8-AA08-623D60185904
P2860
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@ast
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@en
type
label
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@ast
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@en
prefLabel
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@ast
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@en
P2093
P2860
P356
P1476
Initial testing (stage 1) by t ...... tor targeting notch signaling.
@en
P2093
C Patrick Reynolds
E Anders Kolb
Hernan Carol
Jianrong Wu
John M Maris
Malcolm A Smith
Min H Kang
Peter J Houghton
Raushan T Kurmasheva
Richard Gorlick
P2860
P304
P356
10.1002/PBC.23290
P577
2011-08-16T00:00:00Z